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ABSTRACT
From 1999 to 2002, 20 patients with aggressive non-Hodgkin lymphoma, among 28 who failed autologous
peripheral blood progenitor cell transplantation, were rescued with cyclophosphamide, hydroxydaunomycin,
Oncovin (vincristine), and prednisone (CHOP)/rituximab (RTX) and granulocyte-macrophage colony-stimu-
lating factor (GM-CSF). RTX was administered twice during each course of chemotherapy, before CHOP and
after GM-CSF. This cytokine was given to increase the antibody-dependent cell-mediated cytotoxicity and to
reduce the leukopenia on the basis of our preliminary data, which suggested that this cytokine can upregulate
CD20 expression. The relevant (World Health Organization grade 3-4) toxicity mainly consisted of myelo-
suppression (neutropenia in 60% of patients). Fifteen patients achieved complete remission (CR) or had a
partial response, with an overall response rate of 75% (60% CR and 15% partial response). Six of the 12
patients who achieved CR relapsed: 2 died of progressive disease, 1 died of infectious complications after
allogeneic transplantation, and 3 are alive in second CR. Eight patients showed progressive disease: 5 died of
progressive disease, 1 of secondary acute leukemia, and 1 of infectious complications after allogeneic trans-
plantation, whereas 1 is alive in second CR. At last follow-up, 10 patients are alive, 6 of whom are in complete
continuous remission, with a median follow-up of 31 months (range, 3-51 months). The projected 4-year
progression-free survival is 31.4%, and the 4-year overall survival is 50%. This new association (RTX, CHOP,
and GM-CSF) was feasible in approximately 70% of patients; the overall toxicity was manageable. The good
response rate and the promising outcome observed in this subset of patients could be explained by the possible
increased synergy between chemotherapy, RTX, and GM-CSF, which should be explored in further studies.
© 2005 American Society for Blood and Marrow Transplantation
KEY WORDS
Immunotherapy ● Rituximab ● Lymphoma ● Autologous stem cell transplantation ● Failure
l
a
i
o
l
t
a
mNTRODUCTION
Lymphoma patients who relapse after autolo-
ous peripheral blood progenitor cell transplanta-
ion (ASCT), especially those with aggressive non-
odgkin lymphoma (NHL), have a very poor
rognosis. In this setting, salvage chemotherapy or a
econd transplantation cannot substantially modify
he very poor outcome, which is characterized by a
edian overall survival (OS) of 3 months for patients
ith large cell lymphoma [1]. Patients with mantle cell a
B&MTymphoma (MCL) that relapses after ASCT also have
very poor survival [2,3].
A second transplantation attempt in these patients
s rarely feasible. Previous reports suggest that a sec-
nd autologous transplantation or a conventional al-
ogeneic transplantation after the failure of autologous
ransplantation is rarely curative. Progressive disease
nd transplant-related mortality (TRM) are the pri-
ary causes of failure with second autologous and
llogeneic transplantations, respectively [4].
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6In the allogeneic setting, the lack of suitable do-
ors and the very high TRM reported with myeloab-
ative conditioning [4-6] consistently reduce the pro-
ortion of patients who are candidates for this
pproach. However, it is very difﬁcult to obtain a
ufﬁcient peripheral blood stem cell harvest for a sec-
nd autologous bone marrow transplantation [7], and
ven when this procedure is feasible, the efﬁcacy of
he second attempt is often limited because of a lack of
graft-versus-tumor effect. In these patients, any sal-
age options are often jeopardized by both a poor
erformance status and a low hematologic tolerance to
hemotherapy.
Rituximab (RTX) is a highly speciﬁc chimeric an-
ibody against the CD20 antigen, which is present in
ost B-cell lymphomas [8,9]. RTX has demonstrated
igh activity both in follicular lymphoma as a single
gent [10] and in aggressive NHL [11], including
CL [12,13]. In all cases, the combination of RTX
ith cyclophosphamide, hydroxydaunomycin, Onco-
in (vincristine), and prednisone (CHOP) chemother-
py has allowed a signiﬁcant increase in the response
ate in follicular [14] and high grade NHL [15], even
hough this association has never been tested in the
osttransplantation setting as a rescue therapy.
The mechanisms by which RTX induces B-cell
eath include antibody-dependent cell-mediated cyto-
oxicity (ADCC) [16], complement-mediated toxicity,
nd apoptosis against chemoresistant B-lymphoma
ells [17]. Moreover, some observations suggest that
he outcome of patients who receive RTX can be
mproved if the number and activity of their immune
ffector cells (in particular, natural killer cells) are
reserved or enhanced [18].
Granulocyte-macrophage colony-stimulating fac-
or (GM-CSF) is a cytokine that strongly increases the
umber and activity of polymorphonuclear cells and
acrophages against opsonized targets [19-21]. Fur-
hermore, some preliminary data suggest that this
ytokine can upregulate the CD20 expression on lym-
hoid B cells in vitro and in vivo [22]. This study
valuated the safety and the activity of an original
mmunochemotherapeutic approach that included
HOP, RTX, and GM-CSF in a group of patients
ith aggressive NHL after ASCT failure.
ATERIALS AND METHODS
atient Characteristics
We observed 28 patients with aggressive NHL after
SCT failure from 1999 to 2002. Twenty (14 with
iffuse large cell lymphoma [DLCL] and 6 with MCL
lastoid variant) were considered eligible for a salvage
rotocol including RTX and CHOP chemotherapy.
Exclusion criteria included a poor performance
tatus (1 according to the World Health Organiza- C
28ion [WHO], not due to the underlying lymphoma),
oor hematologic count (with platelets 100 000/L
nd/or polymorphonuclear cells 1500/L), leuke-
ic disease with hyperleukocytosis (white blood cell
ount 50 000/L), HLA-compatible donor if aged
55 years, previous anthracycline cumulative dose
300 mg/m2, cardiac ejection fraction 45%, central
ervous system involvement, positive serologic test
ndings for human immunodeﬁciency virus, and ac-
ive hepatitis B. Eight (29%) of the 28 observed pa-
ients were not eligible for the following reasons: 3
ad previously received an anthracycline cumulative
ose 300 mg/m2, 3 had a very poor performance
tatus unrelated to the underlying lymphoma, 1 had a
oor hematologic count, and 1 refused the treatment.
atient characteristics are shown in Table 1.
Patients were heavily pretreated with a median
umber of 3 chemotherapy regimens before ASCT: 9
atients with DLCL had previously been enrolled in a
rotocol of high-dose sequential therapy including the
toposide, doxorubicin, cyclophosphamide, vincris-
ine, prednisone, and bleomycin (VACOP-B) regimen
a median of 8 weeks with a median cumulative dose of
00 mg/m2 doxorubicin), followed by cyclophospha-
able 1. Patient Characteristics
Variable
No. of
Patients %
ge (y)
Median 48
Range 28-69
ex
Male 6 30
Female 14 70
tatus
PR 2 10
Relapse 16 80
Progression 2 10
revious CHT regimens
Median 4
Range 2-7
ulky disease (after transplantation)
Yes 7 35
No 13 65
one marrow involvement
Yes 8 40
No 12 60
HO performance status
0-2 17 85
3-4 3 15
istologic type
Diffuse large cell lymphoma 14 70
Mantle cell lymphoma (blastoid variant) 6 30
tage
I-II 2 10
III-IV 18 90
PI score
0-1 1 5
2 6 30
3 9 45
4-5 4 20HT indicates chemotherapy; IPI, International Prognostic Index.
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CHOP/Rituximab Plus GM-CSF after Failed ASCT
Bide 7 g/m2 and VP-16 2 g/m2 before ASCT. The
ther 5 patients with DLCL received ASCT for re-
apse after 12 VACOP-B courses (with a median cu-
ulative dose of 300 mg/m2 doxorubicin) and re-
eived 2 or 3 dexamethasone, high-dose cytarabine,
nd Platinol (cisplatin) (DHAP) courses before high-
ose therapy; the 6 patients with MCL received
SCT as second-line salvage therapy after 2 or 3
ourses of DHAP.
Before enrollment, all patients were required to
ive their written informed consent; to have conﬁr-
ation of active CD20 NHL by biopsy or ﬁne-
eedle aspiration of an involved site (all biopsy spec-
mens were reviewed by 1 or 2 hematopathologists); to
e younger than 70 years of age; to show a relapse,
rogression, or persistence of disease after ASCT; and
o have measurable disease and absence of severe or-
an dysfunctions (bilirubin 3 mg/dL, creatinine 2
g/m, alanine aminotransferase and aspartate amino-
able 2. Toxicity
Variable
176 RTX Infusions 73
CHOP  RTX and 10 Second
Step Immunotherapy (% Patients
with an Event in at Least 1 Cycle)
PS 1-2 (WHO) PS 3-4 (WHO)
ematologic toxicity
Anemia 15 40
Neutropenia 5 60
Thrombocytopenia 5 50
xtrahematologic toxicity
Infection 10 15
Mucositis 10 0
Liver toxicity 5 5
Cardiac toxicity 0 0
Neurologic toxicity 25 0
Renal toxicity 10 0
Lung toxicity 5 0
Nausea and vomiting 5 0
Constipation 10 5
S indicates performance status.
igure 1. Schedule of treatment in 20 patients with aggressive lym
hamide; VCR, vincristine; ANC, absolute neutrophil count; sm, square m
B&MTransferase 3 times the normal values, and carbon
onoxide diffusion in the lung 40%) not related to
he underlying disease. All patients underwent pre-
reatment staging studies that included computed to-
ography of the chest, abdomen, and pelvis; nuclear
maging with gallium scans, ﬂuorine-18-ﬂuorodeoxy-
lucose positron emission tomography, or both; and
nilateral bone marrow biopsies. Our institutional re-
iew board approved this study.
reatment
Patients received a scheme of treatment that con-
isted of a modiﬁed CHOP-21 schedule (cyclophos-
hamide 750 mg/m2, doxorubicin 50 mg/m2, and vin-
ristine 1.4 mg/m2 up to a maximal dose of 2 mg on
ay 4, and prednisone 40 mg/m2/d for 4 days, from
ay 4 to day 7). Patients also received RTX 375
g/m2 on day 1 and 375 mg/m2 on day 14 of each
ycle of CHOP. The RTX infusion was interrupted in
he event of fever, chills, edema, congestion of the
ead and neck mucosa, hypotension, or any other
erious adverse event and was resumed when such
vent was no longer observed. GM-CSF was admin-
stered subcutaneously at 150 g/d; it was started the
ay after the end of CHOP (day 5) and was continued
or at least 9 days until the second RTX administra-
ion (Figure 1). The rationale for GM-CSF adminis-
ration on the fourth day was based on the well-
ocumented ability of this drug to prevent or reduce
eutropenia after chemotherapy, on data supporting
ncreased ADCC by phagocytic cells after GM-CSF
dministration [20,21], and, ﬁnally, on the possibility
f upregulating CD20 expression, as suggested also by
ur preliminary ﬁndings [22,23] (Figure 2). Patients
ere treated every 3 weeks for at least 2 courses before
he ﬁrst evaluation of response.
If the absolute neutrophil count was1.5 109/L
r the platelet count was 1  109/L, chemotherapy
dministration was delayed for up to 2 weeks, and then
and failed ASCT. Doxo indicates doxorubicin; CTX, cyclophos-phoma
eter; MPDN, prednisone.
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6reatment was stopped. The doses of RTX were not
odiﬁed, and RTX was also continued when CHOP
as stopped. Treatment was stopped if lymphoma
rogressed, if the patient declined to continue, or at
he discretion of the investigator in cases of intercur-
ent illness or adverse events.
Patients showing disease progression after 2 courses
f treatment were excluded from further treatment. The
esponders (complete remission [CR] or partial re-
ponse [PR]) received 2 more courses of CHOP/
TX/GM-CSF or 3 more courses of RTX alone in
ase of poor hematologic tolerance, at the dose of 375
g/m2 at day 7, every 21 days, together with daily
M-CSF from day 1 to day 11 (second step of ther-
py; Figure 3).
Patients achieving clinicoradiologic CR did not
eceive any further treatment. Patients in PR after the
econd step of therapy were treated at the clinician’s
iscretion (local radiotherapy or allogeneic transplan-
ation in case of HLA-matched sibling availability).
esponse to Treatment and Adverse Events
The ﬁrst tumor response assessment was per-
ormed after at least 2 courses of chemotherapy (in-
luding 4 doses of RTX), and the ﬁnal restaging was
erformed at the end of treatment. The responses
ere classiﬁed as CR, PR, or progressive disease ac-
ording to the International Workshop criteria [24].
CR was deﬁned as the disappearance of all lesions
nd radiologic or biological abnormalities observed at
igure 2. Effects of GM-CSF administration for 10 days in a wom
edian-intensity ﬂuorescence (MIF) increased from 120 to 216. Th
ell, which increased from 32 616 to 107 833 in the high density c
medium), and from 755 to 455 in the low density cluster (down) riagnosis and the absence of new lesions. An uncon- t
30rmed CR was deﬁned as a CR with the persistence of
ome radiologic abnormalities, which had to be re-
ressed in size by at least 75%. PR was deﬁned as the
egression of all measurable lesions by more than
0%, the disappearance of no measurable lesions, and
he absence of new lesions. Progressive disease was
eﬁned as the appearance of a new lesion, any growth
f the initial lesion by more than 25%, or growth of
ny measurable lesion that had regressed during treat-
ent by more than 50% from its smallest dimensions.
All adverse events reported by the patient or ob-
erved by the investigator were collected from the
ase-report form in predeﬁned categories. An adverse
vent was deﬁned as any adverse change from the
atient’s baseline condition, whether it was considered
elated to treatment or not. Each event was graded
ccording to the WHO toxicity criteria.
tatistical Analysis
Because of the scarcity of data in patients with
ggressive lymphomas treated after ASCT failure, the
afety and efﬁcacy evaluation of this schedule was
owered by basing our statistical design on the histor-
cal experience reported in 54 patients with refractory
r relapsing aggressive lymphoma (DLCL or MCL)
escued with RTX alone (375 or 500 mg/m2). Coifﬁer
t al. [11] reported an overall response rate (ORR) of
2%, with a CR rate of 9% and a treatment-related
eath rate of 4%.
With a probability of early termination of 55%,
h leukemic MCL; CD20 cells increased from 80% to 95%, and
tiCALC assay allowed enumeration of the CD20 density per single
(upper), from 7 083 to 27 597 in the intermediate density cluster
vely, in the lymphoma cells.an wit
e Quan
lusterhe following rules were established for the prelimi-
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CHOP/Rituximab Plus GM-CSF after Failed ASCT
Bary evaluation of safety and efﬁcacy in the ﬁrst 15
atients: with an observed rate of CR2 in 15 or with
treatment-related death rate 1 in 15, the study
hould be stopped. We hypothesized that our sched-
le could obtain a CR rate 29% (20% than the
istorical data); therefore, the expected sample size
considering   .05 and   .20) was 20 patients with
minimax Simon design [25].
OS and progression-free survival (PFS) were
alculated from the day the CHOP/RTX/GM-CSF
reatment started until death due to any cause or last
ollow-up. The probabilities of survival and relapse
ere estimated and plotted by using the Kaplan-Meier
ethod. Data were analyzed by using the SPSS sta-
istical package (SPSS Inc., Chicago, IL).
ESULTS
The median time from transplantation to the ini-
iation of treatment in the 20 patients was 8 months
range, 2-72 months). The 4 scheduled courses of
HOP/RTX/GM-CSF were given to 15 patients
75% of enrolled patients), and 5 patients showed
isease progression after the ﬁrst or second cycle.
hese patients were included in the response and
utcome analysis according to intention-to-treat
riteria. Two patients who achieved a PR after 4
ourses of CHOP/RTX/GM-CSF received 2 addi-
ional courses, followed by the second step of therapy.
igure 3. First restaging after 2 courses of CHOP/rituximab/GM-
ransplantation; uCR, CR unconﬁrmed.ne patient in PR after the 4 courses of chemoimmu- P
B&MTotherapy withdrew from the protocol because of per-
istent aplasia and eventually had progressive disease;
mong the 12 patients in CR, 8 patients with uncon-
rmed CR after the 4 courses of CHOP/RTX/GM-
SF received the second step of therapy as previously
lanned.
oxicity
All 20 patients were included for the toxicity evalu-
tion of 73 courses of CHOP/RTX/GM-CSF, followed
n 10 patients by the second step of immunotherapy,
or a total of 176 RTX infusions. The GM-CSF ad-
inistration was interrupted in 3 patients because of
ntolerance and was replaced by granulocyte colony-
timulating factor. These 3 patients developed an
able 3. Response to Therapy in the 20 Patients with Aggressive
HL and in the Subgroup of the 14 Patients with DLCL
Response NHL, n (%) DLCL NHL, n (%)
arly death 0/20 (0) 0/14 (0)
R 12/20 (60) 9/14 (64)
R 3/20 (15) 1/14 (7)
D/NR 5/20 (25) 4/14 (29)
RR 15/20 (75) 10/14 (71)
ollow-up
Early death 0/20 (0) 0/14 (0)
CCR 6/20 (30) 6/14 (43)
PD 8/20 (40) 5/14 (36)
Relapse 6/20 (30) 3/14 (21)
weeks after the fourth RTX infusion. AlloTx indicates allogeneicCSF, 2D indicates progressive disease; NR, no response.
631
a
c
c
t
a
a
ﬁ
w
c
T
l
p
p
p
v
g
s
1
m
t
h
R
(
w
i
d
F
c
F
T
F
I
*
A. Olivieri et al.
6cute syndrome after the ﬁrst GM-CSF dose, with
hills and fever in 1 case and severe bone pain and
hest pain (without evidence of coronary disease) in
he other 2 patients. RTX was generally well toler-
ted. We observed 1 grade 4 tumor lysis syndrome
nd 2 grade 1 to 2 episodes of hypotension after the
rst infusion of RTX. The grade 3 to 4 adverse effects
ere consistent with the expected toxicity of CHOP
hemotherapy. We did not observe any toxic deaths.
he most relevant (WHO 3-4) toxicity was hemato-
ogic: 1 patient, with a long disease history and heavy
retreatment, withdrew from the protocol because of
ersistent marrow aplasia.
Sixty percent of patients developed severe neutro-
enia, and 50% and 40% of patients experienced se-
igure 4. OS in 20 patients with aggressive NHL. CI indicates
able 4. Clinical Outcome of the 20 Patients According to the Initial C
ailure
Patient
No. Age (y) Histology IPI
Time ASCT Prior
CHOP-RTX (mo)
Respo
CHOP
1 65 MCL 3 15 CR
2 63 DLCL 3 12 CR
3 67 MCL 5 5 CR
4 69 MCL 2 72 CR
5 28 DLCL 2 5 CR
6 36 DLCL 3 2 CR
7 36 DLCL 3 44 NR
8 36 DLCL 4 2 NR
9 58 DLCL 2 35 CR
10 43 DLCL 4 20 NR
11 37 DLCL 3 7 CR
12 48 DLCL 3 7 CR
13 51 DLCL 2 7 CR
14 66 MCL 3 8 PR
15 49 MCL 4 3 NR
16 33 DLCL 1 5 NR
17 40 MCL 3 29 PR
18 43 DLCL 3 70 PR
19 66 DLCL 2 33 CR
20 48 DLCL 2 8 CR
PI indicates International Prognostic Index; F.U., follow-up; NR,
Alive and well.onﬁdence interval. c
32ere anemia and thrombocytopenia, respectively. The
rade 3 to 4 extrahematologic toxicity mainly con-
isted of infectious complications (15%): we observed
Pseudomonas aeruginosa sepsis, 1 P. aeruginosa pneu-
onitis, and 1 radiologically documented pneumoni-
is. Grade 1/2 and grade 3/4 hematologic and extra-
ematologic toxicities are reported in Table 2.
esponse and Survival Analysis
Fifteen patients responded to treatment, with 12
60%) CRs and 3 PRs (ORR, 75%), whereas 5 patients
ere classiﬁed as nonresponders. Six patients are still
n complete continuous remission (CCR) with a me-
ian follow-up of 31 months (range, 3-51 months).
igure 5. PFS in 20 patients with aggressive NHL. CI indicates
ristics and the Secondary Therapy Given after CHOP/RTX/GM-CSF
Outcome Secondary Therapy
Status at Last
Follow-Up
Follow-Up
(mo)
Relapse Allotransplantation Death 23
Relapse No therapy Death 30
Relapse No therapy Death 36
Relapse LPD  RTX CR 49*
CCR No therapy CR 51*
Relapse Allotransplantation CR 48*
Progression No therapy Death 4
Progression No therapy Death 3
Relapse LPD  RTX CR 38*
Progression Allotransplantation Death 9
CCR No therapy CR 45*
CCR No therapy CR 45*
CCR No therapy CR 45*
Progression No therapy Death 24
Progression No therapy Death 3
Progression No therapy Death 14
Progression Allotransplantation CR 35*
Progression No therapy Death 6
CCR No therapy CR 32*
CCR No therapy CR 31*
ponse; LPD, liposomal pegylated doxorubicin.haracte
nse
-RTX
no resonﬁdence interval.
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CHOP/Rituximab Plus GM-CSF after Failed ASCT
Bight patients experienced disease progression: 5 died
f progressive disease, 1 died of infectious complica-
ions after receiving an allogeneic transplant, 1 died of
econdary acute myeloid leukemia, and 1 is alive and
n second CR after receiving an allogeneic transplant
rom an HLA-identical sibling.
Six of the 12 patients who achieved CR relapsed: 2
ied of progressive disease, 1 died of infectious com-
lications after allogeneic transplantation, and 3 are
live and achieved a second CR (2 after a liposomal
nthracycline-based regimen and 1 after an allogeneic
ransplantation). The ORR was 71% in the 14 patients
ith DLCL and 83% in the 8 MCL patients, with a
4% and 50% CR rate, respectively. Nevertheless,
espite this apparently similar response rate, all 5
CL patients who were responsive to the chemother-
py eventually relapsed or progressed within a median
ime of 14 months, compared with the 3 relapses
bserved in the 9 DLCL patients who achieved CR.
All 20 patients were evaluable for clinical outcome
ith a median follow-up of 31 months (range, 3-51
onths). Ten patients died; 7 of these died of pro-
ressive disease (6 with DLCL NHL and 1 with
CL). As far as the other 3 patients affected by MCL
re concerned, 1 died of pneumonia, 1 died of sepsis
fter allogeneic transplantation performed after the
elapse, and 1 died of secondary acute leukemia.
At the last follow-up, 10 patients were alive,
mong whom 2 were affected by MCL and 8 by
LCL. Six patients were still in CCR, and 4 achieved
subsequent CR: 2 after allogeneic transplantation
nd 2 after RTX/liposomal anthracycline–based reg-
mens. These data are summarized in Tables 3 and 4.
The projected 4-year OS was 48% (95% conﬁ-
ence interval, 28%-69%; Figure 4), and the 4-year
FS was 30% (95% conﬁdence interval, 14.5%-52%;
igure 5). In the 14 patients with DLCL, the OS was
8%, with 43% PFS (Figures 6 and 7).
ISCUSSION
The ﬁrst attempt at rescue therapy with RTX
igure 6. OS in 14 DLCL patients. CI indicates conﬁdence interval.lone achieved only a 31% ORR in pretreated aggres- i
B&MTive NHL [11]. After the demonstration that the RTX
ssociation with CHOP was very effective as up-front
herapy both in patients with indolent NHL [14] and
n those with aggressive NHL [11,26], many other
ttempts to improve the response rate have been
ested that associate RTX with other chemotherapy
egimens [27].
We decided to modify the timing of RTX admin-
stration during CHOP therapy, basing our schedule
n the hypothesis that RTX can sensitize lymphoma
ells to chemotherapy [17] and that GM-CSF admin-
stration can increase RTX activity, both by upregu-
ating CD20 expression [19,20] and by enhancing
DCC [21-23]. Moreover, in vivo and in vitro exper-
ments suggest that low doses of GM-CSF can stim-
late and expand both the natural killer compartment
nd ADCC [19-21]. Many patients showed a poor
ematologic tolerance to chemotherapy after ASCT,
nd profound immune suppression was documented
n all of them even 1 or 2 years after ASCT [28].
In patients with a suitable donor, a second alloge-
eic transplantation can offer a better chance of cure
han a second ASCT, thanks to the potential graft-
ersus-leukemia effect, but this procedure is affected
y a very high TRM [29]. Recently, the use of re-
uced-intensity conditioning regimens has reduced
RM with a very promising OS and PFS, even in
eavily pretreated patients with hematologic malig-
ancies [30]. The role of reduced-intensity condition-
ng after ASCT failure has been recently investigated
n 38 patients with lymphoproliferative malignancies
31]. This approach was feasible, with a 20% TRM at
4 months, 53%OS, and 50% PFS; nevertheless, only
minority of patients, after ASCT failure, could ben-
ﬁt from this approach.
The role of RTX as salvage therapy after ASCT
ailure has not been extensively investigated in pa-
igure 7. PFS in 14 DLCL patients. CI indicates conﬁdence
nterval.
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6ients with CD20 DLCL [32]; recently, 17 pa-
ients received RTX alone after ASCT failure, with
54% ORR, but the median duration of response
as only 13 months [33]. More recently, 28 lym-
homa patients received RTX after ASCT (n  16)
r allogeneic stem cell transplantation (n  12); 9
atients who did not achieve CR after stem cell
ransplantation converted to CR after RTX [34].
In a second report, a heterogeneous population
ncluding 55 patients with NHL and Hodgkin dis-
igure 8. Computed tomographic scan of a young woman after
nvolving the lung and pleural effusion (A) after 4 courses of CHOP
nd renal involvement at relapse. E and F, Complete regression ofase received RTX plus GM-CSF after ASCT. t
34mong the 33 patients with B-cell lymphoma, 14
ad primary refractory disease, 12 had relapsed dis-
ase, and 7 had high-risk disease in ﬁrst CR [35].
A third report evaluated the efﬁcacy and toxicity
f RTX plus GM-CSF after ASCT in 35 patients
ith DLCL (n  25), MCL (n  3), or other
ubtypes of B-cell lymphoma. With a median fol-
ow-up of 30 months, the 2-year event-free survival
ate was 83%, and OS was 88%. The third report,
lthough it conﬁrms the feasibility of the associa-
L relapse 6 months after ASCT, with mediastinal bulky disease
CSF/RTX (B). The same patient (C and D) showed extensive liver
oma. The patient is in CCR 4 years after the end of therapy.a DLC
/GM-ion RTX plus GM-CSF in the posttransplantation
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CHOP/Rituximab Plus GM-CSF after Failed ASCT
Betting, does not answer the question of whether
his association could be worthwhile in patients
hose ASCT fails; indeed, 34 of 35 patients had
hemosensitive disease before ASCT, and an amend-
ent of the protocol also allowed enrollment of patients
n CR before ASCT [36].
Our approach, tested in a homogeneous setting,
as feasible in most (20 of 28) patients with aggres-
ive lymphoma whose ASCT failed. We did not
bserve severe or fatal cardiotoxicities, probably
ecause we included only patients with a relatively
ow cumulative dose (300 mg/m2) of doxorubicin.
In the 14 patients with DLCL, the outcome
eems to be better than reported in previous expe-
iences, thus suggesting that this schedule could
ffectively eradicate the disease in a relevant pro-
ortion (6/14) of patients. Indeed, we observed a
ong CCR in patients with DLCL relapsing with
ulky disease and extra nodal sites after high dose
equence followed by ASCT (Figure 8). Conversely,
lthough they showed a very high ORR, none of the
MCL patients maintained a CCR.
In conclusion, our study shows that this new
chedule represents an effective salvage treatment
or lymphoma patients with failed ASCT, who are
ften not eligible for allogeneic transplantation.
ore data are needed to conﬁrm the synergy be-
ween GM-CSF and RTX, but in our opinion, this
ssociation should be now considered for all pa-
ients with CD20 DLCL and failed ASCT who
ack a suitable donor or who are not eligible for an
llogeneic bone marrow transplantation.
In many centers, the anthracycline-based regi-
ens plus RTX are increasingly used as up-front
reatment for young patients with CD20 DLCL,
nd it is not uncommon to observe many patients
ho have received a heavy cumulative anthracycline
ose after their ﬁrst- or second-line therapy fails. In
his case, although the re-treatment with RTX can
e safe and effective in patients with bulky disease
37], if the previous cumulative dose of doxorubicin
s 400 mg/m2, rescue therapy with CHOP/RTX
lus GM-CSF could generate some concerns about
he high risk of cardiotoxicity or acquired drug
esistance. For this reason, we think that the intro-
uction of liposomal anthracyclines (instead of con-
entional doxorubicin) in the same schedule could
e an attractive alternative option for this subset of
atients.
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